{
  "abstract": "Psychedelic medicine has gained rapid popularity for the treatment of a variety of neuropsychiatric disorders, including depression, anxiety, and post-traumatic stress disorder. As novel psychedelic analogues and treatment regimes emerge, increasing numbers of variables are being tested. Here, we review various approaches and considerations for novel psychedelic therapies, including the strengths and limitations of current assays and models. Finally, we provide guidance and considerations for next-generation psychedelic drug development.",
  "abstract_shown": true,
  "affiliations": [
    "Nancy Pritzker Laboratory, Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California 94305, United States",
    "Center of Excellence for Psilocybin Research and Treatment, Sheppard Pratt, Baltimore, Maryland 21204, United States",
    "Department of Pharmacology, Toxicology & Neuroscience, School of Graduate Studies, Louisiana State University Health Shreveport, Shreveport, Louisiana 71103, United States",
    "Louisiana Addiction Research Center, Louisiana State University Health Shreveport, Shreveport, Louisiana 71103, United States",
    "Department of Psychiatry and Behavioral Medicine, School of Medicine, Louisiana State University Health Shreveport, Shreveport, Louisiana 71103, United States",
    "Departments of Physiology & Biophysics and Psychiatry, University of Illinois College of Medicine, Chicago, Illinois 60612, United States",
    "Jesse Brown VA Medical Center, Chicago, Illinois 60612, United States",
    "Pax Neuroscience, Glenview, Illinois 60015, United States",
    "Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, United States"
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 5,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Lindsay P. Cameron"
    },
    {
      "affs": [
        1
      ],
      "name": "Matthew W. Johnson",
      "orcid": "0000-0001-7068-0513"
    },
    {
      "affs": [
        2,
        3,
        4
      ],
      "name": "Kevin S. Murnane",
      "orcid": "0000-0002-8143-0541"
    },
    {
      "affs": [
        5,
        6,
        7
      ],
      "name": "Mark M. Rasenick",
      "orcid": "0000-0003-2405-4364"
    },
    {
      "affs": [
        8
      ],
      "name": "Charles D. Nichols",
      "orcid": "0000-0002-0615-0646"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/6w6b3kf1f7b45.bib",
  "cited_by": 0,
  "doi": "10.1021/acschemneuro.6c00492",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13741791/",
  "id": "6w6b3kf1f7b45",
  "issns": [
    "1948-7193"
  ],
  "landing_url": "https://doi.org/10.1021/acschemneuro.6c00492",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Review"
    ],
    [
      "openalex",
      "3203|Psychedelics and Drug Studies"
    ]
  ],
  "openalex": "W7213341604",
  "pdf_url": null,
  "pmcid": "PMC13741791",
  "pmid": "42980080",
  "published": "2026-09-14",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/6w6b3kf1f7b45.ris",
  "sources": [
    {
      "first_seen": "2026-11-10T12:22:46Z",
      "native_id": "PMC13741791",
      "source": "pmc",
      "url": "https://doi.org/10.1021/acschemneuro.6c00492"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:3203|Psychedelics and Drug Studies",
      "subfield": "psychiatry"
    }
  ],
  "title": "Next-Generation Psychedelic Drug Development",
  "title_text": "Next-Generation Psychedelic Drug Development",
  "type": "peer-reviewed",
  "updated_at": "2026-11-10T12:22:46Z",
  "url": "https://research.draconitic.com/paper/6w6b3kf1f7b45",
  "venue": "ACS Chemical Neuroscience",
  "versions": []
}